Cargando…
Strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus
Acute intoxication with tetramethylenedisulfotetramine (TETS) can trigger status epilepticus (SE) in humans. Survivors often exhibit long-term neurological effects, including electrographic abnormalities and cognitive deficits, but the pathogenic mechanisms linking the acute toxic effects of TETS to...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595842/ https://www.ncbi.nlm.nih.gov/pubmed/34478772 http://dx.doi.org/10.1016/j.neuro.2021.08.011 |
_version_ | 1784600239548661760 |
---|---|
author | Calsbeek, Jonas J. González, Eduardo A. Boosalis, Casey A. Zolkowska, Dorota Bruun, Donald A. Rowland, Douglas J. Saito, Naomi H. Harvey, Danielle J. Chaudhari, Abhijit J. Rogawski, Michael A. Garbow, Joel R. Lein, Pamela J. |
author_facet | Calsbeek, Jonas J. González, Eduardo A. Boosalis, Casey A. Zolkowska, Dorota Bruun, Donald A. Rowland, Douglas J. Saito, Naomi H. Harvey, Danielle J. Chaudhari, Abhijit J. Rogawski, Michael A. Garbow, Joel R. Lein, Pamela J. |
author_sort | Calsbeek, Jonas J. |
collection | PubMed |
description | Acute intoxication with tetramethylenedisulfotetramine (TETS) can trigger status epilepticus (SE) in humans. Survivors often exhibit long-term neurological effects, including electrographic abnormalities and cognitive deficits, but the pathogenic mechanisms linking the acute toxic effects of TETS to chronic outcomes are not known. Here, we use advanced in vivo imaging techniques to longitudinally monitor the neuropathological consequences of TETS-induced SE in two different mouse strains. Adult male NIH Swiss and C57BL/6J mice were injected with riluzole (10 mg/kg, i.p.), followed 10 min later by an acute dose of TETS (0.2 mg/kg in NIH Swiss; 0.3 mg/kg, i.p. in C57BL/6J) or an equal volume of vehicle (10% DMSO in 0.9% sterile saline). Different TETS doses were administered to trigger comparable seizure behavior between strains. Seizure behavior began within minutes of TETS exposure and rapidly progressed to SE that was terminated after 40 min by administration of midazolam (1.8 mg/kg, i.m.). The brains of vehicle and TETS-exposed mice were imaged using in vivo magnetic resonance (MR) and translocator protein (TSPO) positron emission tomography (PET) at 1, 3, 7, and 14 days post-exposure to monitor brain injury and neuroinflammation, respectively. When the brain scans of TETS mice were compared to those of vehicle controls, subtle and transient neuropathology was observed in both mouse strains, but more extensive and persistent TETS-induced neuropathology was observed in C57BL/6J mice. In addition, one NIH Swiss TETS mouse that did not respond to the midazolam therapy, but remained in SE for more than 2 h, displayed robust neuropathology as determined by in vivo imaging and confirmed by FluoroJade C staining and IBA-1 immunohistochemistry as readouts of neurodegeneration and neuroinflammation, respectively. These findings demonstrate that the extent of injury observed in the mouse brain after TETS-induced SE varied according to strain, dose of TETS and/or the duration of SE. These observations suggest that TETS-intoxicated humans who do not respond to antiseizure medication are at increased risk for brain injury. |
format | Online Article Text |
id | pubmed-8595842 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
record_format | MEDLINE/PubMed |
spelling | pubmed-85958422021-12-01 Strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus Calsbeek, Jonas J. González, Eduardo A. Boosalis, Casey A. Zolkowska, Dorota Bruun, Donald A. Rowland, Douglas J. Saito, Naomi H. Harvey, Danielle J. Chaudhari, Abhijit J. Rogawski, Michael A. Garbow, Joel R. Lein, Pamela J. Neurotoxicology Article Acute intoxication with tetramethylenedisulfotetramine (TETS) can trigger status epilepticus (SE) in humans. Survivors often exhibit long-term neurological effects, including electrographic abnormalities and cognitive deficits, but the pathogenic mechanisms linking the acute toxic effects of TETS to chronic outcomes are not known. Here, we use advanced in vivo imaging techniques to longitudinally monitor the neuropathological consequences of TETS-induced SE in two different mouse strains. Adult male NIH Swiss and C57BL/6J mice were injected with riluzole (10 mg/kg, i.p.), followed 10 min later by an acute dose of TETS (0.2 mg/kg in NIH Swiss; 0.3 mg/kg, i.p. in C57BL/6J) or an equal volume of vehicle (10% DMSO in 0.9% sterile saline). Different TETS doses were administered to trigger comparable seizure behavior between strains. Seizure behavior began within minutes of TETS exposure and rapidly progressed to SE that was terminated after 40 min by administration of midazolam (1.8 mg/kg, i.m.). The brains of vehicle and TETS-exposed mice were imaged using in vivo magnetic resonance (MR) and translocator protein (TSPO) positron emission tomography (PET) at 1, 3, 7, and 14 days post-exposure to monitor brain injury and neuroinflammation, respectively. When the brain scans of TETS mice were compared to those of vehicle controls, subtle and transient neuropathology was observed in both mouse strains, but more extensive and persistent TETS-induced neuropathology was observed in C57BL/6J mice. In addition, one NIH Swiss TETS mouse that did not respond to the midazolam therapy, but remained in SE for more than 2 h, displayed robust neuropathology as determined by in vivo imaging and confirmed by FluoroJade C staining and IBA-1 immunohistochemistry as readouts of neurodegeneration and neuroinflammation, respectively. These findings demonstrate that the extent of injury observed in the mouse brain after TETS-induced SE varied according to strain, dose of TETS and/or the duration of SE. These observations suggest that TETS-intoxicated humans who do not respond to antiseizure medication are at increased risk for brain injury. 2021-08-31 2021-12 /pmc/articles/PMC8595842/ /pubmed/34478772 http://dx.doi.org/10.1016/j.neuro.2021.08.011 Text en https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Calsbeek, Jonas J. González, Eduardo A. Boosalis, Casey A. Zolkowska, Dorota Bruun, Donald A. Rowland, Douglas J. Saito, Naomi H. Harvey, Danielle J. Chaudhari, Abhijit J. Rogawski, Michael A. Garbow, Joel R. Lein, Pamela J. Strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus |
title | Strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus |
title_full | Strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus |
title_fullStr | Strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus |
title_full_unstemmed | Strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus |
title_short | Strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus |
title_sort | strain differences in the extent of brain injury in mice after tetramethylenedisulfotetramine-induced status epilepticus |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8595842/ https://www.ncbi.nlm.nih.gov/pubmed/34478772 http://dx.doi.org/10.1016/j.neuro.2021.08.011 |
work_keys_str_mv | AT calsbeekjonasj straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT gonzalezeduardoa straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT boosaliscaseya straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT zolkowskadorota straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT bruundonalda straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT rowlanddouglasj straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT saitonaomih straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT harveydaniellej straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT chaudhariabhijitj straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT rogawskimichaela straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT garbowjoelr straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus AT leinpamelaj straindifferencesintheextentofbraininjuryinmiceaftertetramethylenedisulfotetramineinducedstatusepilepticus |